Remedy publishes the financial statements release, two business reviews and the half-year review according to the disclosed annual schedule.

Event Date
Silent period and closed window February 20 – March 20, 2024
Financial Statements Release 2023 March 20, 2024
Annual Report, Financial Statements and Board of Directors’ Report 2023 Week 12, 2024
Silent period and closed window March 30 – April 29, 2024
Annual General Meeting 2024 April 12, 2024
Business Review for January-March 2024 April 29, 2024
Silent period and closed window July 10 – August 9, 2024
Half-year Financial Report for January-June 2024 August 9, 2024
Silent period and closed window October 2 – November 1, 2024
Business Review for January-September 2024 November 1, 2024

Regularly published financial reports are always preceded by a silent period of 30 days, during which Remedy does not issue statements on the financial position, business operations, markets or prospects.

During the silent period, the senior management of the company does not meet with investors, analysts or other capital market representatives, nor do they give interviews on the financial position of the company.